Moderna's Cancer Vaccine Worked. The Data Leaked Early, and Its Stock Fell 17%.
Moderna and Merck's mRNA melanoma vaccine cut recurrence risk 42% in Phase 3. The data leaked two days before ESMO, and Moderna lost $17 billion in a day.
Sheida Mohassesy··5 min read